- Sourcews Report
- File
- HTML
- Size
- 29 Ko
- URL response
- 100%
- Source quality
- 94%
- Sourcews Explorer
Patients with early Parkinson's disease show better symptom control and improvements in daily activities with Stalevo than carbidopa/levodopa
15.04.08 - 21:48 ... source : Novartis - US
... New data intended to support regulatory filings in 2008 with goal of expanding Stalevo indication to include treatment of early Parkinson's disease Stalevo currently used only when carbidopa/levodopa loses therapeutic effect prior to next scheduled dose (referred to as end-of-dose "wearing off") Approximately 6.5 million (1.5 million in the U.S.) people worldwide suffer from Parkinson's disease, a progressive and disabling neurological condition East Hanover, NJ, April 15, 2008 - A new study in patients with early Parkinson's disease demonstrates that Stalevo (carbidopa, levodopa and entacapone) gives better symptom control and greater improvements in activities of daily living than carbidopa/levodopa, the most widely-used current therapy. The FIRST STEP study, presented today at the American Academy of Neurology Annual ...» Next (HTML)
Similar news
100% | 15.04.08 - 18:43 ... source : Novartis
... goal of expanding Stalevo indication to include treatment of early Parkinson's disease Stalevo currently used only when levodopa/carbidopa loses therapeutic effect prior to next scheduled dose[2] (referred to as end-of-dose "wearing off") Approximately 6.5 million people worldwide suffer from Parkinson's ...
98% | 11.04.08 - 16:22 ... source : Novartis
... conditions but can increase risk of osteoporotic fractures with up to 50% of patients on long-term therapy at risk[1],[2] Study of more than 800 men and women shows higher bone mineral density with Aclasta than risedronate, a current established therapy[3] ...
97% | 15.04.08 - 21:48 ... source : Novartis - US
... goal of expanding Stalevo indication to include treatment of early Parkinson's disease Stalevo currently used only when carbidopa/levodopa loses therapeutic effect prior to next scheduled dose (referred to as end-of-dose "wearing off") Approximately 6.5 million (1.5 million in the U.S.) ...
91% | 15.04.08 - 19:23 ... source : Schering-Plough
... with Nucleoside Class of HIV Drugs KENILWORTH, N.J., April 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated a Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult ...
91% | 11.04.08 - 16:48 ... source : IBM - United States
... ARMONK, NY - 11 Apr 2008: IBM today announced that Palomar Pomerado Health (PPH), the largest public health district in California, has gone live with a new virtualized information infrastructure which is enabling PPH to manage and store electronic medical ...
